Please click anywhere to start.
VAXCHORA Role in Prevention
Efficacy and Safety of VAXCHORA
Dosage and Administration
Important Safety Information
VAXCHORA is contradicted in people with a severe allergic reaction (e.g. anaphylaxis) to any ingredient of VAXCHORA or to a previous dose of any cholera vaccine.
The safety and effectiveness of VAXCHORA have not been established in immunocompromised persons.
VAXCHORA may be shed in the stool of recipients for at least 7 days. There is a potential for transmission of the vaccine strain to non-vaccinated close contacts (e.g., household contacts). Use caution when considering whether to administer VAXCHORA to individuals with immunocompromised close contacts.
The most common adverse reactions for adults (incidence > 3%) were tiredness (31%), headache (29%), abdominal pain (19%), nausea/vomiting (18%), lack of appetite (17%) and diarrhea (4%).
Indications and Usage
VAXCHORA is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1. VAXCHORA is approved for use in persons 2 through 64 years of age traveling to cholera-affected areas.
Limitations of Use:
The effectiveness of VAXCHORA has not been established in persons living in cholera-affected areas. The effectiveness of VAXCHORA has not been established in persons who have pre-existing immunity due to previous exposure to V. cholerae or receipt of a cholera vaccine. VAXCHORA has not been shown to protect against disease caused by V. cholerae serogroup O139 or other non-O1 serogroups.
For more information about VAXCHORA, please see Full Prescribing Information.
EMERGENT®, VAXCHORA®, and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries.
© 2022 Emergent BioSolutions Inc. All rights reserved.